JUBBONTI® 60mg

What Is Jubbonti 60mg?

Jubbonti® 60mg is a prescription-only, fully human monoclonal IgG2 antibody developed by Sandoz as a biosimilar to Prolia (denosumab). It received FDA approval on March 5, 2024, as the first interchangeable biosimilar to Prolia, confirming no clinically meaningful differences in safety, purity, or potency. It is supplied as a single-dose 60mg/mL prefilled syringe for subcutaneous injection, intended for use in licensed clinical settings only.

Product Specifications

• Active ingredient: Denosumab-bbdz, biosimilar to Prolia
• Strength: 60mg/mL
• Format: Single-dose prefilled syringe for subcutaneous injection
• Manufacturer: Sandoz Inc.
• Regulatory status: FDA-approved interchangeable biosimilar to Prolia; EMA-authorized biosimilar
• CAS Number: 615258-40-7 (denosumab)
• Molecular type: Fully human monoclonal antibody, IgG2
• Storage: Store refrigerated at 2–8°C; protect from light; do not freeze
• Intended use: For licensed medical professionals and clinical settings only

Is Jubbonti® 60mg Available in the U.S.?

Jubbonti® is available in the US through licensed pharmaceutical and clinical supply channels as a prescription-only medicine restricted to qualified medical professionals. As of May 2026, practitioners should verify current regulatory status, formulary requirements, and cold-chain handling protocols before procurement.

Licensed professionals looking to buy Jubbonti® 60mg may contact the Doctor Medica customer service team directly for supply and ordering guidance. Follow our guidance if you want to buy osteoporosis treatments.

Is Jubbonti® the Same as Prolia?

Jubbonti® is not the same branded product as Prolia, but it is approved as a biosimilar and interchangeable medicine to Prolia. The FDA determined that Jubbonti® is highly similar to Prolia, with no clinically meaningful differences in safety, purity, and potency for the approved conditions of use.

Both products use denosumab-based RANKL inhibition and share corresponding osteoporosis and bone loss indications. The difference is manufacturer and brand identity: Jubbonti® is manufactured by Sandoz Inc., while Prolia is the reference product manufactured by Amgen.

What Are Jubbonti’s Indications?

Jubbonti® 60mg is indicated for:

• Postmenopausal osteoporosis in women at high fracture risk
• Bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer
• Bone loss in women receiving aromatase inhibitor therapy for breast cancer
• Glucocorticoid-induced osteoporosis in men and women at high fracture risk

Across these populations, it reduces the risk of vertebral, non-vertebral, and hip fractures. This page covers the 60mg osteoporosis formulation only — the 120mg formulation (Xgeva equivalent) covers oncology bone complications and is a separate product.

How Does Jubbonti® 60mg Work?

Jubbonti® targets and inhibits RANK Ligand (RANKL), a cytokine that activates RANK receptors on osteoclast precursors. Osteoclasts are the cells in the body responsible for breaking down bone — by blocking RANKL, Jubbonti® reduces their formation, function, and survival. The result is decreased bone resorption and preserved or improved bone mineral density (BMD), reducing fracture incidence across approved indications.

What Is Jubbonti® Being Used For?

Jubbonti® is indicated for postmenopausal osteoporosis in women at high risk for fracture, including the management of menopause-associated bone loss, where reduced estrogen levels can accelerate bone resorption. It is also indicated for:

• Increasing bone mass in men with osteoporosis at high fracture risk
• Glucocorticoid-induced osteoporosis in men and women
• Bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer
• Bone loss in women receiving aromatase inhibitor therapy for breast cancer

How Is Jubbonti® Administered?

Jubbonti® is administered as a 60mg subcutaneous injection once every 6 months, delivered to the upper arm, upper thigh, or abdomen by or under the supervision of a qualified healthcare professional.

For the effective use of Jubbonti®:

• Pre-treatment: Screen for and correct hypocalcaemia before initiating therapy
• Supplementation: Calcium and vitamin D are required throughout treatment — patients should confirm dosing with their doctor or pharmacist
• Missed dose instructions: Administer the missed dose as soon as possible; schedule all subsequent doses every 6 months from that date
• Discontinuation: A safe and effective transition plan should be in place before stopping treatment to prevent rapid bone loss and rebound fracture risk
• Storage: Refrigerate at 2–8°C; may be kept at room temperature (up to 25°C) for up to 30 days before use; do not refreeze; protect from light

What Are the Jubbonti® Side Effects & Drug Interactions?

The most clinically significant Jubbonti® side effect is hypocalcaemia, with an elevated risk in patients with renal impairment. Other commonly reported side effects include musculoskeletal pain, back pain, and injection site reactions.

Serious but less common risks include:

• Osteonecrosis of the jaw (ONJ)
• Atypical femoral fractures
• Serious skin infections (cellulitis)
• Increased vertebral fracture risk following discontinuation

Patients should inform their doctor or pharmacist of all concurrent medications, particularly other bone-active therapies or treatments that affect calcium metabolism. Drug interactions are not extensively documented, but monitoring remains important when combining therapies that affect bone or calcium balance.